Effectiveness of Hepatitis C Virus (HCV) Testing for Persons Born during 1945-1965-Summary Results from Three Randomized Controlled Trials

被引：0
|
作者：
Smith, Bryce D. [1 ]
Yartel, Anthony K. [2 ]
Brown, Kimberly Ann [3 ]
Krauskopf, Katherine [4 ]
Massoud, Omar I. [5 ]
Jordan, Cynthia E. [5 ]
Kil, Natalie [4 ]
Federman, Alex D. [4 ]
Nerenz, David R. [3 ]
Liffmann, Danielle [6 ]
Rein, David B. [6 ]
机构：
[1] Ctr Dis Control & Prevent, Atlanta, GA USA
[2] CDC Fdn, Atlanta, GA USA
[3] Henry Ford Hosp, Detroit, MI 48202 USA
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[5] Univ Alabama Birmingham, Birmingham, AL USA
[6] Univ Chicago, NORC, Atlanta, GA USA
来源：
HEPATOLOGY | 2014年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
194
引用
收藏
页码：295A / 295A
页数：1
相关论文
共 31 条
  • [21] Expanding hepatitis C virus test uptake using self-testing among men who have sex with men in China: two parallel randomized controlled trials
    Cheng Wang
    Peizhen Zhao
    Ann Marie Weideman
    Wenqian Xu
    Jason J. Ong
    Muhammad S. Jamil
    Bin Yang
    Joseph D. Tucker
    BMC Medicine, 21
  • [22] Everolimus Based Immunosuppression in Hepatitis C Virus Positive De Novo Liver Transplant Recipients: 24 Month Results from a Randomized Controlled Trial.
    Saliba, F.
    Brown, R. S., Jr.
    Metselaar, H.
    Beckebaum, S.
    Duvoux, C.
    Navasa, M.
    Dong, G.
    Lopez, P.
    Nevens, F.
    LIVER TRANSPLANTATION, 2013, 19 : S100 - S101
  • [23] Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in patients with chronic hepatitis C virus: Preliminary results from a randomized, double-blind, placebo-controlled, ascending multiple dose study
    Chandra, Priyamvada
    Raible, Donald
    Harper, Dawn
    Speth, John
    Villano, Stephen
    Bichier, Geraldine
    GASTROENTEROLOGY, 2006, 130 (04) : A748 - A748
  • [24] Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial
    Rockstroh, Juergen K.
    Plonski, Frank
    Bansal, Meena
    Faetkenheuer, Gerd
    Small, Catherine B.
    Asmuth, David M.
    Pialoux, Gilles
    Zhang-Roper, Rebecca
    Wang, Ronnie
    Pineda, Juan A.
    Heera, Jayvant
    ANTIVIRAL THERAPY, 2017, 22 (03) : 263 - 269
  • [25] Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry
    Hinrichsen, Holger
    Stoehr, Albrecht
    Cornberg, Markus
    Klinker, Hartwig
    Heyne, Renate
    John, Christine
    Simon, Karl-Georg
    Guenther, Veronika
    Martin, Karen
    Witte, Vanessa
    Zeuzem, Stefan
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (03) : 415 - 423
  • [26] Epoetin alfa (Procrit®) once weekly maintains ribavirin dose in hepatitis C virus (HCV)-infected patients treated with combination therapy:: Interim results of a randomized, double-blind, placebo-controlled study.
    Dieterich, DT
    Pockros, PJ
    Schiff, ER
    Shiffinan, ML
    Sulkowski, MS
    Wright, T
    Bowers, PJ
    HEPATOLOGY, 2002, 36 (04) : 286A - 286A
  • [27] What is the impact of higher sensitivity assay on response-guided therapy in hepatitis C virus (HCV)? comparative analysis between TaqMan™ and Amplicor™ tests from two large randomized international trials of pegasys® plus copegus®
    Sarrazin, Christoph
    Shiffman, Mitchell L.
    Hadziyanis, Stephanos J.
    Lin, Amy
    Colucci, Giuseppe
    Ishiada, Hiroshi
    Zeuzem, Stefan
    HEPATOLOGY, 2007, 46 (04) : 813A - 814A
  • [28] Different signal-to-cut-off ratios from three automated anti-hepatitis C virus chemiluminescence immunoassays in relation to results of recombinant immunoblot assays and nucleic acid testing
    Oh, Eun-Jee
    Chang, Jiyoung
    Yang, Jin-Young
    Kim, Yonggoo
    Park, Yeon-Joon
    Han, Kyungja
    BLOOD TRANSFUSION, 2013, 11 (03) : 471 - 473
  • [29] Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)
    Wyles, David L.
    Kang, Minhee
    Matining, Roy M.
    Murphy, Robert L.
    Peters, Marion G.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (12):
  • [30] Pegylated interferon alpha 2b plus ribavirin is effective in patients with chronic hepatitis C virus infection and normal liver enzymes: Preliminary results from a prospective, randomized, controlled, multi-center trial.
    Flamm, SL
    Cahan, J
    Goldman, J
    Nelligan, G
    Chua, D
    Shapiro, B
    Bawani, M
    Yapp, R
    Jurkovic, E
    Manka, D
    HEPATOLOGY, 2002, 36 (04) : 293A - 293A
1234